The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression

Metabolism: Clinical and Experimental

Volumn 63, Issue 1, 2014, Pages 112-119

  Kim, Hyung Jun ^a   Moon, Jae Hoon ^b   Kim, Hyun Min ^a   Yun, Mi Ra ^a   Jeon, Byung Hun ^a   Lee, Byungwan ^a   Kang, Eun Seok ^a   Lee, Hyun Chul ^a   Cha, Bong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Atherosclerosis; Dyslipidemia; PDE3; PPAR

Indexed keywords

APOLIPOPROTEIN E3; CILOSTAZOL; GLUCOSE TRANSPORTER 4; LIVER PROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR; SMALL INTERFERING RNA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOBLOTTING; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLIN; 2-CHLORO-5-NITROBENZANILIDE; 3,3′-DIAMINOBENZIDINE; 4′,6-DIAMIDINO-2-PHENYLINDOLE; APOE; APOLIPOPROTEIN E; ATHEROSCLEROSIS; CHYLOMICRON REMNANTS; CR; DAB; DAPI; DEOXYRIBONTP; DEOXYRIBONUCLEASE; DIMETHYL SULFOXIDE; DMPC; DMSO; DNASE; DNTP; DYSLIPIDEMIA; GLUCOSE TRANSPORTER 4; GLUT 4; GW9662; H&E; HDL; HEMATOXYLIN AND EOSIN; HEPARAN SULFATE PROTEOGLYCANS; HIGH-DENSITY LIPOPROTEIN; HSPG; HUMAN UMBILICAL VEIN ENDOTHELIA CELL; HUVEC; I.P. GLUCOSE TOLERANCE TEST; IPGTT; LDL; LIPOPROTEIN LIPASE; LOW-DENSITY LIPOPROTEIN; LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1; LPL; LRP1; MEM; MINIMUM ESSENTIAL MEDIUM; PCR; PDE3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-Γ; PEROXISOME PROLIFERATOR RESPONSE ELEMENT; PHOSPHODIESTERASE 3; POLYMERASE CHAIN REACTION; PPARΓ; PPAR-Γ; PPRE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE; RIBONUCLEASE; RNASE; RT; RT-PCR; SIRNA; SMALL INTERFERING RNA;PKA, PROTEIN KINASE A; STREPTOZOTOCIN; STZ; TG; TRIGLYCERIDE; VERY LOW-DENSITY LIPOPROTEINS; VLDL;

ANIMALS; APOLIPOPROTEIN E3; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIET, HIGH-FAT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEP G2 CELLS; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; LIVER NEOPLASMS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; TETRAZOLES; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 84890115520     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.09.006     Document Type: Article

References (32)

1. D.L. Dawson, B.S. Cutler, and W.R. Hiatt A comparison of cilostazol and pentoxifylline for treating intermittent claudication Am J Med 109 7 2000 523 530
2. D.L. Dawson, B.S. Cutler, and M.H. Meissner Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Circulation 98 7 1998 678 686
3. S.R. Money, J.A. Herd, and J.L. Isaacsohn Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease J Vasc Surg 27 2 1998 267 274 discussion 74-5
4. M.B. Elam, J. Heckman, and J.R. Crouse Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication Arterioscler Thromb Vasc Biol 18 12 1998 1942 1947
5. T. Wang, M.B. Elam, and W.P. Forbes Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication Atherosclerosis 171 2 2003 337 342
6. J. Herz, and D.K. Strickland LRP: a multifunctional scavenger and signaling receptor J Clin Invest 108 6 2001 779 784
7. A. Rohlmann, M. Gotthardt, and R.E. Hammer Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants J Clin Invest 101 3 1998 689 695
8. T.E. Willnow, S.A. Armstrong, and R.E. Hammer Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo Proc Natl Acad Sci U S A 92 10 1995 4537 4541
9. T.E. Willnow, Z. Sheng, and S. Ishibashi Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist Science 264 5164 1994 1471 1474
10. A.P. Lillis, L.B. Van Duyn, and J.E. Murphy-Ullrich LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies Physiol Rev 88 3 2008 887 918
11. Y. Fujioka, and Y. Ishikawa Remnant lipoproteins as strong key particles to atherogenesis J Atheroscler Thromb 16 3 2009 145 154
12. S.Y. Park, J.H. Lee, and K.Y. Kim Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription Atherosclerosis 201 2 2008 258 265
13. R. Herzano, and A.J. Simon Thymopoietin protein: from thymic hormone to proteins involved in nuclear architecture and cell cycle control Harefuah 137 7-8 1999 327 332
14. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB J 22 3 2008 659 661
15. A. Gauthier, G. Vassiliou, and F. Benoist Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma J Biol Chem 278 14 2003 11945 11953
16. T.L. Innerarity, R.E. Pitas, and R.W. Mahley Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts J Biol Chem 254 10 1979 4186 4190
17. Y. Okuda, Y. Kimura, and K. Yamashita Cilostazol Cardiovasc Drug Rev 11 4 1993 451 465
18. Y. Kimura, T. Tani, and T. Kanbe Effect of cilostazol on platelet aggregation and experimental thrombosis Arzneimittelforschung 35 7A 1985 1144
19. J. Kambayashi, Y. Liu, and B. Sun Cilostazol as a unique antithrombotic agent Curr Pharm Des 9 28 2003 2289 2302
20. E. Takazakura, K. Ohsawa, and K. Hamamatsu Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients Jpn Pharmacol Ther 17 1989 311 315
21. G. Lazennec, L. Canaple, and D. Saugy Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase a activators Mol Endocrinol 14 12 2000 1962 1975
22. M. Watanabe, K. Inukai, and H. Katagiri Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes Biochem Biophys Res Commun 300 2 2003 429 436
23. U. Beisiegel, W. Weber, and G. Bengtsson-Olivecrona Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein Proc Natl Acad Sci 88 19 1991 8342
24. A. Laatsch, M. Merkel, and P.J. Talmud Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance Atherosclerosis 204 1 2009 105 111
25. J.H. Moon, S.B. Kang, and J.S. Park Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme a reductase inhibitor atorvastatin and hepatic LRP1 expression Metabolism 60 7 2011 930 940
26. J.H. Moon, H.J. Kim, and H.M. Kim Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia J Mol Endocrinol 49 3 2012 165 174
27. J.E. Basford, L. Wancata, and S.M. Hofmann Hepatic deficiency of low density lipoprotein receptor-related protein-1 reduces high density lipoprotein secretion and plasma levels in mice J Biol Chem 286 15 2011 13079 13087
28. M.E. O'Donnell, S.A. Badger, and M.A. Sharif The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease J Vasc Surg 49 5 2009 1226 1234
29. S.H. Zhang, R.L. Reddick, and J.A. Piedrahita Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E Science 258 5081 1992 468 471
30. A.S. Plump, J.D. Smith, and T. Hayek Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells Cell 71 2 1992 343 353
31. R.L. Reddick, S.H. Zhang, and N. Maeda Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression Arterioscler Thromb 14 1 1994 141 147
32. T. Tani, K. Uehara, and T. Sudo Cilostazol, a selective type iii phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats Atherosclerosis 152 2 2000 299 305